Market Open: Stocks Mixed, Bond Yields Fall On Treasury Action, Moderna Shares Pop 8/19/26

Смотреть на YouTube ↗  |  19 августа 2026, 14:27  |  3:46  |  CNBC
Спикеры
Andrew Ross Sorkin — Соведущий, Squawk Box
Becky Quick — Соведущий, Squawk Box
Pippa Stevens — Репортер по рынкам и энергетике, CNBC
Rupesh Parikh — Analyst, Oppenheimer
Jessica Ettinger — Anchor, CNBC
CNBC's market open update covers a mixed-to-higher tape with bond yields falling after the Treasury doubled longer-dated buyback operations. Moderna and Merck rallied on positive Phase 3 melanoma vaccine data, while Lowe's guided lower and Target raised its outlook. Commentary also flagged weak private demand signals in long-dated Treasuries and rising fuel costs. - Major averages opened higher, with the Dow helped by Merck strength. - Treasury doubled liquidity buybacks for 10-30 year nominal coupons, pushing bond prices up and yields down. - Becky Quick warned the buybacks may signal weak private market liquidity and are not a great sign. - Moderna and Merck's Phase 3 melanoma vaccine data met primary and secondary endpoints. - Lowe's cut its full-year forecast on housing weakness; Target raised its outlook and received a tariff refund. - Oppenheimer's Rupesh Parikh sees Target in the middle innings of its turnaround with potential multiple expansion. - US crude oil traded above $85 and California diesel rose above $7, adding consumer inflation concerns. - US tariffs on Canadian goods were paused after a reported deal with Ottawa.
Идеи
Andrew Ross Sorkin Соведущий, Squawk Box 0:32
Treasury buybacks lift long-dated bond prices.
The Treasury Department is doubling its liquidity support buyback operations for longer-dated nominal coupon securities across the 10- to 30-year sector. That is causing bond prices to rally and yields to fall, with the 30-year yield pulling back after recently approaching a nearly 20-year high.
Pippa Stevens Репортер по рынкам и энергетике, CNBC 2:13
Phase 3 melanoma vaccine data beat.
Moderna and Merck's individualized mRNA-based melanoma vaccine combined with Keytruda met both primary and secondary endpoints in a large Phase 3 trial, improving recurrence-free survival and distant metastasis-free survival after surgical removal of melanoma. Moderna shares jumped and Merck shares rose about 7%.
Jessica Ettinger Anchor, CNBC 2:52
Lowe's guidance cut on housing weakness.
Lowe's lowered its full-year forecast in a sluggish housing market, and the shares traded lower, signaling continued earnings pressure for home-improvement retail tied to housing activity.
Rupesh Parikh Analyst, Oppenheimer 2:59
Target turnaround may drive multiple expansion.
Target is in the middle innings of a turnaround after a second consecutive quarter of positive comparable sales growth. As the market begins to believe the turnaround, Target could re-rate from a high-teens multiple to around 20x. Target also raised its full-year outlook and received a large tariff refund.
Далее

This CNBC video, published August 19, 2026, features Andrew Ross Sorkin, Pippa Stevens, Jessica Ettinger, Rupesh Parikh discussing 10-Year U.S. Treasury, TLT, MRK, MRNA, LOW, TGT. 4 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Andrew Ross Sorkin, Pippa Stevens, Jessica Ettinger, Rupesh Parikh  · Tickers: 10-Year U.S. Treasury, TLT, MRK, MRNA, LOW, TGT